Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis resear
about
New Therapeutic Approaches in Polycythemia VeraAdvances in the management of myelofibrosisDynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.Immunomodulatory agents in myelofibrosis.Emerging drugs for myelofibrosis.Ruxolitinib: a new treatment option for myelofibrosis.Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial.Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trialDisease characteristics and outcomes in younger adults with primary and secondary myelofibrosis.A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosisArray comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phaseF-18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Appearance of Extramedullary Hematopoesis in a Case of Primary Myelofibrosis.Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders.Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patientsMyeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases.JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis.Choosing between stem cell therapy and drugs in myelofibrosis.Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms.Characterising neovascularisation in fracture healing with laser Doppler and micro-CT scanning.Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms.Acquired familial Mediterranean fever associated with a somatic MEFV mutation in a patient with JAK2 associated post-polycythemia myelofibrosis.Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical, and Therapeutic Implications.Myeloproliferative Neoplasms in ChildrenThe role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease courseThe natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms.Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens.Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosisGenetic-pathologic characterization of myeloproliferative neoplasms.Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives.Allogeneic hematopoietic cell transplantation for patients with myelofibrosisComparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.FAS/FASL gene polymorphisms in Turkish patients with chronic myeloproliferative disordersFuture therapies for the myeloproliferative neoplasms.Treatment options for essential thrombocythemia and polycythemia vera.Prognostic markers for myeloid neoplasms: a comparative review of the literature and goals for future investigation.Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques.Acute Myeloid Leukemia Evolving from JAK 2-Positive Primary Myelofibrosis and Concomitant CD5-Negative Mantle Cell Lymphoma: A Case Report and Review of the Literature.
P2860
Q26795677-08BB38C0-0C13-4BDA-896D-3803D2102A92Q27008072-F8622E28-9FCB-40AC-993D-5694E8661CDCQ33400683-C2B561A8-6D37-4F71-A537-5141CE0A24F0Q33401615-33781940-F503-4459-BB46-D2C912917F28Q33404574-C9BF8849-3493-434A-B5D6-055078C6661BQ33405241-F7DE40F3-2B17-42D4-B142-93669B954761Q33421596-E449FE24-3EA3-4E42-93A7-9FC0C3CED5D8Q33432637-4A30B922-1587-444C-8C7C-BDA4E9CFD394Q33433006-DD0195A6-D23F-4D41-84B1-1B72DB126284Q33434284-EA7AC758-5028-49FB-9707-1CFA694AD3AFQ33558154-888E1E52-6FD8-4ADF-A1C8-2FD8F4D0352DQ33711600-0DAE2B87-055F-487A-8EDC-72B74DC8397DQ33952753-853E5C1D-EF47-4EFB-B78F-6A9274765C16Q34419687-B4CAA3D3-E246-448C-A72C-3FEC7366F8F7Q34474214-30E5D817-E56C-48D2-BB5F-1C991C790F5DQ34652224-B991E75A-058E-405C-90E3-88E8889831D0Q34734491-C5656985-938E-4FCE-8BD2-24CF847F2289Q34750599-09407F87-30FD-46E7-84EF-1160F316734DQ34861945-DD591955-A93D-40CC-B10D-CA7145B2A0A7Q35433425-49634F03-4752-4EAB-979A-2726C8B18AAFQ35677969-148D9CE0-B9A9-4B36-9CF0-B3253C709977Q36116382-49F4222E-27D5-46A6-9254-2E6C78CA3C4FQ36305041-622688BF-B55B-46BF-A155-0FF56C7BC2A3Q36788138-0CAFF2CE-D08E-43F5-9155-230D827CF2E8Q36843673-45DCE821-6A96-4C58-A2C6-3DD7E0DF2CD6Q37009717-91E3F467-78B0-4C08-8B64-3266A2048757Q37034988-DBECD004-0CBC-4BED-9513-22A519C31F9AQ37151437-E57CDD36-1153-4EFA-920B-92528EBE07CAQ37163487-1DD54D8A-895D-4256-9E2B-D07B6694ECA9Q37310619-5750DDC6-3BB3-4210-AF85-19A2E0553DA5Q37495397-B8E43B55-802B-46DE-8DBF-62A04FFA6149Q37552023-257EEF98-8318-47F7-9BB2-20BB8CD730F3Q37555790-033DBACA-9648-4A72-92B4-30DB1D362734Q37675522-B0405DF2-EE6E-4449-99FA-A79A6B8813B9Q37809804-9A51AF78-D73C-43C6-AC59-0F9222973B0CQ37810107-BF7486B3-0BC3-4542-9B13-4495DE9754F6Q37817621-305B5791-04EE-4865-9470-8329EE62CF05Q37968531-5DA35600-5BE8-4F04-BFCE-BF14CAE60EF9Q38014534-3B8F6CE3-3935-4DE0-8109-306F9F17C7F1Q38041128-676F0D95-1B1A-423A-B81E-C7F14EF55E6E
P2860
Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis resear
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Primary myelofibrosis (PMF), p ...... group for myelofibrosis resear
@ast
Primary myelofibrosis (PMF), p ...... group for myelofibrosis resear
@en
type
label
Primary myelofibrosis (PMF), p ...... group for myelofibrosis resear
@ast
Primary myelofibrosis (PMF), p ...... group for myelofibrosis resear
@en
prefLabel
Primary myelofibrosis (PMF), p ...... group for myelofibrosis resear
@ast
Primary myelofibrosis (PMF), p ...... group for myelofibrosis resear
@en
P2093
P50
P1433
P1476
Primary myelofibrosis (PMF), p ...... group for myelofibrosis resear
@en
P2093
Alessandro M Vannucchi
Attilio Orazi
Brigitte Dupriez
Deborah Thomas
Elizabeth Hexner
Francisco Cervantes
Giovanni Barosi
Heinz Gisslinger
International Working Group for Myelofibrosis Research and Treatment (IWG-MRT)
James W Vardiman
P304
P356
10.1016/J.LEUKRES.2006.12.002
P50
P577
2007-01-08T00:00:00Z